Handelsavisen
prelaunch
Companies Healthcare 2230.SE
22
2230.SE Tadawul Pharmaceuticals

Saudi Chemical Holding Company SJSC

$8,30
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
1,19 %
Op margin
6,9 %
ROE
14,1 %
Net margin
4,9 %
Debt / equity
0,50
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Saudi Chemical Holding Company SJSC operates in the Pharmaceuticals & Medical Research industry, focusing on pharmaceuticals and medical research activities.

Business. Saudi Chemical Holding Company SJSC is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Saudi Arabia and operates within the broader Healthcare sector. It is primarily listed on the Tadawul stock exchange under the ticker symbol 2230.SE. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
14,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2230.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2230.SE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Saudi Chemical Holding Company SJSC is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Saudi Arabia and operates within the broader Healthcare sector. It is primarily listed on the Tadawul stock exchange under the ticker symbol 2230.SE. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Saudi Chemical Holding Company SJSC maintains a debt-to-equity ratio of 0.5, indicating a relatively balanced capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.36, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow stands at SAR 321.69 million, which is lower than the operating cash flow of SAR 490.66 million, reflecting capital expenditures of SAR 43.2 million.

    Profitability metrics show a return on equity (ROE) of 14.07% and a return on assets (ROA) of 5.38%. These figures are to be compared against the industry's preferred metrics, which typically emphasize ROE and ROA as key indicators of performance. The company's ROE is strong, but the ROA is moderate, suggesting that asset utilization could be improved.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic breakdown provided in the available data, but the company is headquartered in Saudi Arabia, indicating a primary exposure to the domestic market.

    Outlook for the current fiscal year indicates a stable revenue trajectory, with no significant growth or contraction expected in the near term. Historical revenue data does not show a clear upward or downward trend, suggesting a stable but not rapidly growing business.

    Risk factors include a medium liquidity risk, with the company's net cash position being negative after accounting for total debt. Dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. No recent events such as filings or transcripts have been disclosed in the available data.

    Key takeaways
    • The company maintains a balanced capital structure with a debt-to-equity ratio of 0.5.
    • Return on equity is strong at 14.07%, but return on assets is moderate at 5.38%.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Liquidity risk is medium, and dilution risk is low.
    • No significant growth or contraction is expected in the near term.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $8,30
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $2.38B
    Net cash
    -$1.18B
    Current ratio
    1.4
    Debt / equity
    0.5
    ROA
    5.4%
    ROE
    14.1%
    Cash conversion
    146.0%
    CapEx / revenue
    -0.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,9 %Above median
    Net Margin4,9 %Above median
    ROE14,1 %Above P75
    Capex / Rev-0,6 %Above P75
    D/E0,50Below median
    Cash Conv1,46Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Saudi Chemical Holding Company SJSC Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2230.SECanonical
    Tadawul · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage